Stayble Therapeutics: BioStock: Stayble enrols the first patient in herniated disc study
Stayble has now enrolled and treated the first patient in the company's clinical phase Ib study with STA363 for the treatment of herniated discs. This milestone marks a continued positive development for the drug candidate STA363, which is already undergoing a phase IIb study for degenerative disc disease. The company's CEO Andreas Gerward shared his thoughts on the milestone in an interview.
Read the full article at biostock.se:
https://www.biostock.se/en/2023/09/stayble-enrols-the-first-patient-in-herniated-disc-study/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se